Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, considers what government pandemic planning means for MedTech.
The Department of Health and Social Care (DHSC) has published its new Pandemic Preparedness Strategy, setting out how the UK intends to strengthen the resilience of the health and social care system, and ensure critical supplies and infrastructure are in place ahead of future health emergencies.
The strategy highlights the importance of maintaining scalable diagnostic capacity between pandemics. This is likely to create opportunities for partnership between industry and government, particularly for businesses involved in in-vitro diagnostics, point-of-care testing, laboratory equipment and disease surveillance technologies.
There is also a stronger focus on securing access to critical medical products and devices. This may translate into greater scrutiny of supplier resilience, increased interest in UK manufacturing capability, and a move towards more strategic, long-term supplier partnerships. Framework agreements could also play a larger role in ensuring rapid access to essential products during future emergencies.
The continued use of strategic stockpiles and advance purchasing arrangements for critical products such as PPE and infection prevention technologies is another important signal in the strategy. This suggests preparedness procurement may become a more structured and ongoing element of NHS purchasing activity, rather than something mobilised only during crises.
Finally, the strategy emphasises improving the use of health data and surveillance systems, alongside improving how innovative technologies are evaluated and adopted across the NHS. This aligns with wider reforms aimed at accelerating the uptake of effective medical technologies and reducing barriers to adoption.
Overall, the strategy suggests pandemic preparedness will increasingly become a standing policy priority rather than a reactive programme. It also reinforces the government’s expectation that the medtech sector will play a central role in strengthening the UK’s health security and preparedness capabilities.
The author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
